Legend Biotech Corporation (LEGN)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Ying Huang Ph.D. | CEO & Director | -- | -- | 1973 |
| Ms. Lori A. Macomber CPA | Chief Financial Officer | -- | -- | 1971 |
| Mr. Doug Wallace | Vice President of Global Operations | -- | -- | -- |
| Dr. Guowei Fang Ph.D. | Chief Scientific Officer & Head of Business Development | -- | -- | -- |
| Joanne Choi | Senior Manager of Investor Relations | -- | -- | -- |
| Mr. James Pepin J.D. | General Counsel | -- | -- | -- |
| Deborah Wong | Executive Director of Strategic Marketing & Corporate Communications | -- | -- | -- |
| Ms. Elaine Qian | VP & Global Head of Human Resources | -- | -- | -- |
| Dr. Yuhong Qiu Ph.D. | Senior Vice President of Global Regulatory Affairs | -- | -- | -- |
| Mr. Steven J. Gavel | Senior Vice President of Commercial Development, US & Europe | -- | -- | -- |
Legend Biotech Corporation
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 1,800
Description
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
Corporate Governance
Recent Events
- Apr 22, 20246-K: Corporate Changes & Voting MattersSee Full Filing
- Apr 16, 20246-K: Corporate Changes & Voting MattersSee Full Filing
- Apr 08, 20246-K: Corporate Changes & Voting MattersSee Full Filing
- Apr 05, 2024SC 13G/A: Tender Offer/Acquisition ReportsSee Full Filing
- Mar 19, 202420-F: Periodic Financial ReportsSee Full Filing